This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
If there’s one take-home message about working during a pandemic, it is the enormous value that virtual events, webinars and e-learning can bring when face-to-face meetings and presentations are impossible. Rewind to March of 2020, and pharma companies were facing a communication crisis. The crisis that changed everything.
The ways in which we communicate and consume information are constantly transforming. In 2020, the challenges of the COVID-19 pandemic greatly accelerated the pace of this evolution, with wide-reaching effects on many aspects of medical communications. Q1: What are some ways in which data dissemination has evolved in 2020?
In a recent webinar from pharmaphorum, the National Institute for Health Research (NIHR) outlined why and how it has developed a new approach to engage with patients while complying with national regulations, such as those set out in the Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice.
To build strong HCP networks: Host webinars and conferences : Share new research and treatment insights. Consider Pfizer’s Science Will Win campaign, which highlighted the companys dedication to vaccine development. Ensure faster adoption of new therapies. Utilize CRM platforms : Track and maintain relationships with physicians.
This method not only prioritizes the participant’s comprehension but also aligns with best practices in health communication that suggests a focused approach can significantly enhance understanding and retention of important information. The importance of using plain language in health communications is well-documented in literature.
For example, GSKs vaccine campaigns often include real patient experiences, fostering trust. Humanize Your Brand with Thought Leadership: Engage healthcare professionals with webinars, whitepapers, and expert articles. Commit to Transparency: Clearly communicate side effects, trial results, and efficacy.
This collaboration was vital; it fostered communication among stakeholders, allowing them to swiftly address production hurdles and supply chain uncertainties that arose from both international raw material shortages and unpredictable COVID outbreaks.
SB: Over the past 25 years, Recombinant Insulin supplementation has become standardised in the production of monoclonal antibodies as well as virus vaccines. Please check your email to download the Webinar. Can it support the newer therapeutic modalities?
During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry. While production volumes have now fallen, future vaccine demand is hard to predict, as booster shots could be needed at any point to control emerging variants.
Overview Pharmaceutical and biotech companies around the globe are working with Governments to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges.
Just 13% of people completely trust the pharma companies they interact with, 68% say the interactions feel transactional, and only a third agree that organisations know their communication preferences. Communication and transparency. Hughes said: “Patient services is a very scripted part of the business. About the author.
The FDA, in this guidance, has a role in equipping patient advocates to be partners in developing and communicating RWE. The NHC recommends that the FDA provide specific information on how patient groups can communicate with the FDA and identify appropriate contacts for questions or concerns.
The biggest issue we saw as restrictions eased was that many people weren’t aware they might still be at high risk even after two vaccinations, which left them unable to make informed decisions. We are also closely watching the development of additional options that may protect people who are immunocompromised beyond the vaccine.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content